Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants

Isocitrate dehydrogenase 2 (IDH2), an important mitochondrial metabolic enzyme involved in the tricarboxylic acid cycle, is mutated in a variety of cancers. AG‐221, an inhibitor primarily targeting the IDH2‐R140Q mutant, has shown remarkable clinical benefits in the treatment of relapsed or refracto...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Mingzhao, Zhu, Hongmei, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Wang, Lei, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778631/
https://www.ncbi.nlm.nih.gov/pubmed/31361380
http://dx.doi.org/10.1111/cas.14152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778631/
https://www.ncbi.nlm.nih.gov/pubmed/31361380
http://dx.doi.org/10.1111/cas.14152

Ejemplares similares